Axitinib

For research use only.

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

70 publications

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib (AG 013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 62 In stock
EUR 68 In stock
EUR 117 In stock
EUR 213 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Axitinib has been cited by 70 publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Axitinib (AG 013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell M4jEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMECwNFUyOyEQvF2= M4LWZXNCVkeHUh?=
NCI-H1703 M2DJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TIWmlEPTB;MD6wNFA6ODJizszN MYrTRW5ITVJ?
KASUMI-1 M1\HOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC1TWM2OD1yLkCwOlgzKM7:TR?= NFThNJBUSU6JRWK=
CGTH-W-1 MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP6TWM2OD1yLkCwO|IzKM7:TR?= MmnyV2FPT0WU
A204 M3f1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMEC5PVIh|ryP M1\zNHNCVkeHUh?=
HOP-62 NUezc49lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwMUC4N|Yh|ryP NUL1N3Y2W0GQR1XS
H-EMC-SS M{X4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LNT2lEPTB;MD6xNVAxPSEQvF2= M3;FU3NCVkeHUh?=
KU812 Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrDTWM2OD1yLkG2OVc4KM7:TR?= NF3Pb4hUSU6JRWK=
EM-2 MkC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLTUnljUUN3ME2wMlE3QDF4IN88US=> NVrsZ2R6W0GQR1XS
LAMA-84 M1zPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPaTXZKSzVyPUCuNVc3PjVizszN MofFV2FPT0WU
JAR NXL0b3NkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrtZ25KSzVyPUCuNlM6QDlizszN NUfCSoozW0GQR1XS
G-361 M2OxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3lc3BPUUN3ME2wMlMzOzJ3IN88US=> NGrFe5RUSU6JRWK=
KG-1 MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwM{e2OFIh|ryP MWfTRW5ITVJ?
BV-173 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HyRWlEPTB;MD6zPVMzKM7:TR?= Ml7xV2FPT0WU
K5 M2fKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwNEKxNlch|ryP MYHTRW5ITVJ?
MEG-01 MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHq0bItKSzVyPUCuOFI{PjFizszN NFjrfo9USU6JRWK=
MFM-223 NVLqcJFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwNES3O|Yh|ryP NWnpO2NsW0GQR1XS
BE-13 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDXeW5{UUN3ME2wMlUyODB6IN88US=> M{[4Z3NCVkeHUh?=
NEC8 NIrvOIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2K2emlEPTB;MD63NlEyOyEQvF2= MYjTRW5ITVJ?
SW756 MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwOUm4OFYh|ryP M1SzR3NCVkeHUh?=
A2780 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFwMEGxOFYh|ryP MmjjV2FPT0WU
NB14 NIThWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTHWZNWUUN3ME2xMlAyQDBzIN88US=> MlzsV2FPT0WU
H4 NFzOc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljSTWM2OD1zLkC2OFIzKM7:TR?= MXHTRW5ITVJ?
SK-OV-3 NVHmbFAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonsTWM2OD1zLkC2OlM{KM7:TR?= MmexV2FPT0WU
AN3-CA M13wXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjhTWM2OD1zLkC4N|g6KM7:TR?= M4\CcnNCVkeHUh?=
A427 M3\EVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPWUnNKSzVyPUGuNVA{QDFizszN MWjTRW5ITVJ?
ES7 MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jPW2lEPTB;MT6xNVM{PCEQvF2= M4H2TXNCVkeHUh?=
AGS MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljWTWM2OD1zLkGxN|k2KM7:TR?= NHvGWpBUSU6JRWK=
G-402 Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvWdJRsUUN3ME2xMlE1Pjl2IN88US=> M33wfXNCVkeHUh?=
ES5 NUX6PVFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml65TWM2OD1zLkG3NlQ5KM7:TR?= MUXTRW5ITVJ?
DEL NHXVdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLZTWM2OD1zLkK1OFU4KM7:TR?= Ml6xV2FPT0WU
NB10 NXfnUHFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLQZW9uUUN3ME2xMlMzPTV5IN88US=> NY\NdIN2W0GQR1XS
NCI-H1581 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFwM{mwOFIh|ryP MV3TRW5ITVJ?
D-566MG MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnySpJFUUN3ME2xMlQxPjh|IN88US=> MWnTRW5ITVJ?
LXF-289 M1rsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELDSXhKSzVyPUGuOFM6QTZizszN M32yTHNCVkeHUh?=
BT-549 NYrCRZBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnhfVNKSzVyPUGuOVY6ODlizszN MnfwV2FPT0WU
NKM-1 NEfDdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfUTWM2OD1zLk[wOVU3KM7:TR?= NYTEcVN3W0GQR1XS
SW780 M{jVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFwNkWxOVgh|ryP NXizWo9iW0GQR1XS
NCI-H292 M4rHO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVGycFYzUUN3ME2xMlY3Ozh|IN88US=> MoHLV2FPT0WU
HMV-II M{iyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvKW2k6UUN3ME2xMlcxPDh6IN88US=> NFG1fYZUSU6JRWK=
ALL-PO MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13k[WlEPTB;MT64NFAyPSEQvF2= MmPPV2FPT0WU
UACC-257 M4ezb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjRWIJYUUN3ME2xMlgzOTZ|IN88US=> M3vqXHNCVkeHUh?=
PA-1 NUewVGFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwOEK3NlUh|ryP NWK2O4NXW0GQR1XS
HD-MY-Z NVXhTmU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\TcW9KSzVyPUGuPFYzQDFizszN MmH2V2FPT0WU
HSC-4 NV;XS5FzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\Y[WlEPTB;MT65N|g{QSEQvF2= NYnucGs5W0GQR1XS
GCT NIS1WVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HqNWlEPTB;Mj6wNFkyPiEQvF2= MlHGV2FPT0WU
RT-112 NX:4UWxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTTOXh3UUN3ME2yMlE{PDJ2IN88US=> NF\yNpRUSU6JRWK=
A172 M2TMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnK2TWM2OD1{LkGzOlA3KM7:TR?= NYfIZmtFW0GQR1XS
HCE-T NFf3TnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:zTWM2OD1{LkKwOVk5KM7:TR?= Moj1V2FPT0WU
YH-13 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJwMkG2O|Eh|ryP M{nySnNCVkeHUh?=
DK-MG M3u5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XWXmlEPTB;Mj6yN|g{PCEQvF2= M4PyVHNCVkeHUh?=
ACN NGfVb4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1u4XWlEPTB;Mj6yN|g4PSEQvF2= M{nVW3NCVkeHUh?=
VA-ES-BJ MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHm0dXJKSzVyPUKuNlQ6PTdizszN NVq5XnV1W0GQR1XS
L-363 M3riWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrETWM2OD1{LkK4NFYyKM7:TR?= MXPTRW5ITVJ?
HuH-7 NIT3XoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJwNEKxOlUh|ryP MkjHV2FPT0WU
A4-Fuk NXzEWms3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPOd3QyUUN3ME2yMlQ4OTZ6IN88US=> MVzTRW5ITVJ?
T-24 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHOVWpKUUN3ME2yMlQ5ODN5IN88US=> NXrkVlFLW0GQR1XS
GOTO MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmCyTWM2OD1{LkWzNFE{KM7:TR?= M2W0V3NCVkeHUh?=
MV-4-11 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn6T5hKSzVyPUKuOVkyPjlizszN MUXTRW5ITVJ?
DMS-114 M4XTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTJwNk[zOFUh|ryP NFTQb2NUSU6JRWK=
MHH-NB-11 M4DvO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnmTWM2OD1{LkewNlk6KM7:TR?= NYm2VHV3W0GQR1XS
CHP-212 MmTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HmN2lEPTB;Mj64NlA6OSEQvF2= MY\TRW5ITVJ?
DMS-273 Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXC[2hQUUN3ME2yMlkxOjB5IN88US=> MlT5V2FPT0WU
SF295 M1:wZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDPTWM2OD1|LkCyOVk4KM7:TR?= MX7TRW5ITVJ?
NCI-H1563 NWjCbG1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTNwMUWwNFUh|ryP NGPhWphUSU6JRWK=
NCI-H446 NV\wUXp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7zTWM2OD1|LkKyPFA2KM7:TR?= M13HSXNCVkeHUh?=
HCC1806 M2jZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTNwMke2OVch|ryP M{jRZnNCVkeHUh?=
SF126 NFe4NINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTOTWM2OD1|LkOwNFE4KM7:TR?= NEC0U25USU6JRWK=
SW982 M3q1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLGTWM2OD1|LkOzPFc2KM7:TR?= Mn;IV2FPT0WU
ES8 NGjBN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zFNmlEPTB;Mz6zOFk6QSEQvF2= MXjTRW5ITVJ?
SCC-4 NVK0doRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH61O4pKSzVyPUOuOVA{QTZizszN MWXTRW5ITVJ?
RPMI-8226 Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr2UGpKSzVyPUOuOlI3OTZizszN M4K2VHNCVkeHUh?=
EW-11 M1u3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTlTWM2OD1|Lk[zNFIzKM7:TR?= NF;RcXZUSU6JRWK=
COR-L105 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTNwNkOzN|Qh|ryP Mn;QV2FPT0WU
ES1 Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPTTWM2OD1|LkizNFk1KM7:TR?= NF3L[IFUSU6JRWK=
KMOE-2 MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnsdZdkUUN3ME2zMlkyQDB6IN88US=> M2T0SXNCVkeHUh?=
ABC-1 NFLq[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\JT2lEPTB;Mz65N|kyOSEQvF2= M1PSUnNCVkeHUh?=
NCI-H526 M2flSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTNwOUmxNlYh|ryP NXnTfGRtW0GQR1XS
HCC1395 NGS1SmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTNwOUm0PFQh|ryP M1PEeHNCVkeHUh?=
DU-145 MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkCwTWM2OD12LkGyPFI2KM7:TR?= M3;ldnNCVkeHUh?=
JEG-3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfscZRKSzVyPUSuNVU6OTZizszN M3H3d3NCVkeHUh?=
HCC1187 NYLaNIdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTRwMkG1PVch|ryP NY\KTG1GW0GQR1XS
LC-2-ad MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTRwMkKxO|ch|ryP Moq4V2FPT0WU
ONS-76 MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq1XW1KSzVyPUSuNlQyQTJizszN NX\jS4llW0GQR1XS
CAL-27 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoGxTWM2OD12LkK0N|Q1KM7:TR?= M{nhV3NCVkeHUh?=
8-MG-BA M1r1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPZOGxKSzVyPUSuNlY3PThizszN M3fJd3NCVkeHUh?=
HGC-27 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDzVnNbUUN3ME20MlI6PjZizszN M1\XTHNCVkeHUh?=
Hs-578-T NXvoc5Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHyNHlKSzVyPUSuN|E1PjhizszN NVLrVmlsW0GQR1XS
EW-1 NWLBXmV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLuVocxUUN3ME20MlU{ODF2IN88US=> MkO2V2FPT0WU
SW1573 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4e1UWlEPTB;ND61OVE3OyEQvF2= MWfTRW5ITVJ?
SNU-423 M3X5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1v1VmlEPTB;ND62NFc6KM7:TR?= MWjTRW5ITVJ?
HOS NXPnRYVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTRwNkm3O{DPxE1? MmHNV2FPT0WU
LB1047-RCC MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTRwOEG0NVgh|ryP Mm\RV2FPT0WU
ChaGo-K-1 NH\DV5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHHeYxMUUN3ME20Mlg6ODR6IN88US=> NEftZXJUSU6JRWK=
A3-KAW MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TlRmlEPTB;ND65O|M2OiEQvF2= NHvpW2hUSU6JRWK=
CAS-1 NUOyW4JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTRwOUm5NFgh|ryP NXro[YpRW0GQR1XS
NBsusSR NFWwZ41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTVwMEO1NVQh|ryP MVzTRW5ITVJ?
KM12 NGPM[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LiUWlEPTB;NT6yPVgzPyEQvF2= MWDTRW5ITVJ?
NCI-H1155 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T3bWlEPTB;NT6zPFE5PSEQvF2= MkK4V2FPT0WU
EFM-19 MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTVwNEG3N|ch|ryP NU\lW5hWW0GQR1XS
D-392MG M2rNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTVwNUe4OFkh|ryP MYLTRW5ITVJ?
JVM-3 NGDJcXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrV[GJyUUN3ME21MlczOzJ3IN88US=> MljqV2FPT0WU
EW-16 M4HJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fleGlEPTB;NT63OVU5OyEQvF2= MljDV2FPT0WU
KARPAS-45 M2XqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPZVWJKSzVyPUWuPFQ{OjVizszN MknHV2FPT0WU
NCI-H28 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTVwOEe5NVgh|ryP NIHKV4JUSU6JRWK=
COLO-829 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH1[HEyUUN3ME21MlkyPTB2IN88US=> Mm\tV2FPT0WU
KM-H2 NHrNOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP1UZlKSzVyPUWuPVI{QTVizszN Ml;FV2FPT0WU
NCI-H82 NWW1cpBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j4bWlEPTB;NT65Nlc4OSEQvF2= M3zKRnNCVkeHUh?=
OAW-42 NVzqbIx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPuUIZKSzVyPUWuPVg5OjFizszN NXfmUFN{W0GQR1XS
A704 NVz4R4xwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2D3U2lEPTB;Nj6xNFU4PCEQvF2= NVjre5JWW0GQR1XS
NCI-H1048 NYDqboRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvCfpJKSzVyPU[uNVA2QTlizszN NEPhNVNUSU6JRWK=
LOXIMVI MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYK1cIU1UUN3ME22MlEyOjR6IN88US=> Mon4V2FPT0WU
MKN45 NHGwOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HXUWlEPTB;Nj6yOlAyPiEQvF2= NGTCZnJUSU6JRWK=
D-502MG MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PzO2lEPTB;Nj6yPFg2PyEQvF2= M1;peXNCVkeHUh?=
HUTU-80 NXj4TpJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTjTWxLUUN3ME22MlQyPjh6IN88US=> NHrBW|FUSU6JRWK=
S-117 NGX1ZVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLOTWM2OD14LkWwNlY4KM7:TR?= MYLTRW5ITVJ?
HCC1569 NF3jNnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTZwNUO3N|ch|ryP NWTQNlNmW0GQR1XS
J-RT3-T3-5 NE[2SVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK5bJhZUUN3ME22MlU1PTd{IN88US=> MUfTRW5ITVJ?
OC-314 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HtWGlEPTB;Nj65NVE2QSEQvF2= NY\jUZRKW0GQR1XS
SNU-449 M4H1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTdwMEGwO|Ih|ryP NVTCWnNjW0GQR1XS
NCI-H720 MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHK2fGpKSzVyPUeuNVk{PDVizszN NGH4[5lUSU6JRWK=
KP-N-YS M2PvZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTYcodCUUN3ME23MlIxPzJizszN MV7TRW5ITVJ?
IGROV-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL2TWM2OD15LkOyN|g3KM7:TR?= M1ThNnNCVkeHUh?=
SK-PN-DW MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfuTWM2OD15LkS4NVUh|ryP NGjnelNUSU6JRWK=
HCC1419 MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTdwNUOg{txO NWe5cGFJW0GQR1XS
HAL-01 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:4TWM2OD15Lk[wOlQ1KM7:TR?= MofLV2FPT0WU
HCC2998 NFHnNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTdwNkC3OFMh|ryP MlXZV2FPT0WU
SK-N-FI MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVS0Rm9jUUN3ME23MlY{ODN|IN88US=> Mk[xV2FPT0WU
GI-ME-N NUnpWnFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojuTWM2OD15Lk[0PVM1KM7:TR?= NUDoeZE4W0GQR1XS
SW1088 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TqXWlEPTB;Nz62OVgzPiEQvF2= NVXabYNGW0GQR1XS
IA-LM M3G1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXqxOlhmUUN3ME23MlY5PjF|IN88US=> NHXafHFUSU6JRWK=
SK-NEP-1 NWC0d|lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HCemlEPTB;Nz62PVYyKM7:TR?= MWTTRW5ITVJ?
MDA-MB-415 NITadVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTdwOEmxPFYh|ryP NGTO[phUSU6JRWK=
COLO-800 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTdwOUS0PVIh|ryP M2P1VnNCVkeHUh?=
NCI-H2228 NIqwbXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofOTWM2OD16LkG1O|g{KM7:TR?= NIf0bXJUSU6JRWK=
D-423MG NXLmRoRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\0TWM2OD16LkKxO|Ih|ryP M3jXcXNCVkeHUh?=
TE-1 NFHjSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PVfGlEPTB;OD60OFMyPiEQvF2= M2HnbXNCVkeHUh?=
NOS-1 NGDpTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjUTWM2OD16LkWxOVM1KM7:TR?= Ml;oV2FPT0WU
8505C NWH5S5l7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7sUpVKSzVyPUiuOlQ5OjRizszN NXnRN4dyW0GQR1XS
HEC-1 NFjGPHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zMOGlEPTB;OD63PFQ{QSEQvF2= MVjTRW5ITVJ?
TE-11 MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRThwOUm1OVEh|ryP NWLQS4Z6W0GQR1XS
CTB-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTlTWM2OD17LkCxOFM{KM7:TR?= Ml;yV2FPT0WU
TGBC11TKB M{f0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjTfZBrUUN3ME25MlAzOjRzIN88US=> MWfTRW5ITVJ?
NB17 M4POcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vqOWlEPTB;OT6xPFg4KM7:TR?= NXj2TmZxW0GQR1XS
Becker M{TSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHXTWM2OD17LkSxPVQ1KM7:TR?= NGHUcmZUSU6JRWK=
SN12C NUTOfHQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFGzZ29KSzVyPUmuOFUzOzRizszN M3vHfHNCVkeHUh?=
COLO-320-HSR M3P0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTlwNkCyN|ch|ryP M4DXSXNCVkeHUh?=
D-283MED M1zvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPaUFBSUUN3ME25MlY{ODd{IN88US=> MlfQV2FPT0WU
D-263MG NYXObFY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITGb5ZKSzVyPUmuPFM{QDRizszN M1[5TnNCVkeHUh?=
MEL-JUSO MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTlwOUCxNlch|ryP MnSwV2FPT0WU
T98G M{nBVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTlwOUCyNFMh|ryP MXfTRW5ITVJ?
HLE MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTlwOUC5NFkh|ryP NICyPHhUSU6JRWK=
Ca9-22 MnjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFyLkC2OlUh|ryP NFTTOGhUSU6JRWK=
OS-RC-2 M1r4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnCdldKSzVyPUGwMlExPDVizszN MmDxV2FPT0WU
T47D NGHKVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDHbXYxUUN3ME2xNE4yPTVizszN MYjTRW5ITVJ?
GI-1 NHLLflhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LFRWlEPTB;MUCuN|U{OyEQvF2= M1W0SXNCVkeHUh?=
NUGC-3 NFrYWItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonUTWM2OD1zMD60OFAzKM7:TR?= NIr5PYRUSU6JRWK=
MDA-MB-361 NW\YZ3RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV76ZY1OUUN3ME2xNE41PDN{IN88US=> NUnaUlNVW0GQR1XS
SCC-15 NYD3[YFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHf6eotKSzVyPUGwMlQ4OThizszN MVvTRW5ITVJ?
KS-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\SNpJsUUN3ME2xNE43OzBzIN88US=> MWLTRW5ITVJ?
CAL-12T NEHZXm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFyLk[zOlEh|ryP NInLZZpUSU6JRWK=
OVCAR-4 M4flWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n0UGlEPTB;MUCuO|A3QCEQvF2= MkjUV2FPT0WU
HuP-T4 Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvTVWJSUUN3ME2xNU4xOzJ6IN88US=> NHHHeHhUSU6JRWK=
NCI-H358 NFLyVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr6SYNKSzVyPUGxMlI3PTdizszN MVjTRW5ITVJ?
HO-1-N-1 NXH6WZBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnuwTWM2OD1zMT6zN|k5KM7:TR?= MXjTRW5ITVJ?
NH-12 Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy2WYFGUUN3ME2xNU42Ozd6IN88US=> NUKwU3RQW0GQR1XS
MOLT-4 NUTnfm9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jWfGlEPTB;MUGuOVk5PSEQvF2= NH\BWlZUSU6JRWK=
K-562 NI\6NVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlewTWM2OD1zMT63NlQ5KM7:TR?= MmjuV2FPT0WU
ES6 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnnTWM2OD1zMT64OVgyKM7:TR?= MULTRW5ITVJ?
RO82-W-1 M3jYUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fuemlEPTB;MUGuPVA3PCEQvF2= Ml7KV2FPT0WU
Ramos-2G6-4C10 Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFzLkmzNkDPxE1? NWHCeHB2W0GQR1XS
23132-87 Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LsfmlEPTB;MUKuNFgzOSEQvF2= NXjUR5RRW0GQR1XS
A549 M{Pxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmD0TWM2OD1zMj6zNlg2KM7:TR?= MV7TRW5ITVJ?
NCI-H23 NYSwS5V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTxTWM2OD1zMj61NFI3KM7:TR?= NFnYVVRUSU6JRWK=
H9 NUXPTG06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3WTWM2OD1zMj61OVc4KM7:TR?= NHXJOHJUSU6JRWK=
LB771-HNC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF{Lke2OUDPxE1? MmTqV2FPT0WU
QIMR-WIL NHPvUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF{LkiyOVgh|ryP NIDGNINUSU6JRWK=
HSC-3 MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH2b29zUUN3ME2xNk46Ojd4IN88US=> NHnxbXdUSU6JRWK=
PFSK-1 NYXQS4tPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz6SVJ7UUN3ME2xNk46PTB5IN88US=> MULTRW5ITVJ?
ETK-1 M3L5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HQZmlEPTB;MUOuNFc4QSEQvF2= MWDTRW5ITVJ?
SW1710 M3jYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXETWM2OD1zMz6zOlQyKM7:TR?= NHjzfnZUSU6JRWK=
COLO-684 MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXCTWM2OD1zMz60OVQyKM7:TR?= MXHTRW5ITVJ?
RPMI-7951 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13OdWlEPTB;MUOuOVE{PiEQvF2= MofXV2FPT0WU
A101D NUS5b4JMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELzZYFKSzVyPUGzMlU{PDlizszN NFnkVGtUSU6JRWK=
KE-37 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLETWM2OD1zMz61PFg4KM7:TR?= MXjTRW5ITVJ?
SiHa MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFi2WpVKSzVyPUGzMlg{PDZizszN MnHBV2FPT0WU
NCI-H226 MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTF|Lki4NFgh|ryP MULTRW5ITVJ?
DB MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmn6TWM2OD1zMz65PVI5KM7:TR?= MlTTV2FPT0WU
HT-1197 M4HMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n1c2lEPTB;MUSuNFgxQSEQvF2= MoS1V2FPT0WU
SBC-5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFW2bIZKSzVyPUG0MlE{PjJizszN M4r6WnNCVkeHUh?=
VMRC-RCZ MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLKTWM2OD1zND61O|c1KM7:TR?= M3O2fnNCVkeHUh?=
697 M3i3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;HTWM2OD1zND62Nlch|ryP M1H5dHNCVkeHUh?=
OMC-1 NYW0TXFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX6zVGRqUUN3ME2xOE44QDh6IN88US=> MUHTRW5ITVJ?
SKG-IIIa NFHpc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XVbmlEPTB;MUSuPFAxOSEQvF2= NGLNbmhUSU6JRWK=
DOK NFfRfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF2Lkm5N|Mh|ryP NWX2Vno5W0GQR1XS
NCI-H2029 NUfZVWJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjGTWM2OD1zNT6zOlAzKM7:TR?= M3PVS3NCVkeHUh?=
NCI-H2009 M{G1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XMcWlEPTB;MUWuOVA6PSEQvF2= M3P1V3NCVkeHUh?=
LK-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1SwbGlEPTB;MUWuOlQ1QSEQvF2= MnH5V2FPT0WU
NCI-H661 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTF3LkmwO|Uh|ryP MkDIV2FPT0WU
GT3TKB NYPlNGkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELQNFdKSzVyPUG2MlA3PzZizszN NIXkbo9USU6JRWK=
GP5d NVv4[mZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTF4LkO0NkDPxE1? NYfFRZdJW0GQR1XS
SK-MEL-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPYTWM2OD1zNj60OFg2KM7:TR?= MlvjV2FPT0WU
SK-UT-1 M2rZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTKTWM2OD1zNj61OlUh|ryP MXrTRW5ITVJ?
NB7 MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\qTWM2OD1zNj62PVcyKM7:TR?= NVPrOHA3W0GQR1XS
NCI-H460 Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF4LkezNlYh|ryP NHPPR4dUSU6JRWK=
8305C NVfGfJhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfHUYVKSzVyPUG2Mlc5PzdizszN NVvYdJNNW0GQR1XS
CaR-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInkboxKSzVyPUG2MlgyOTFizszN NUnRdYZLW0GQR1XS
D-247MG NUDvUGpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XON2lEPTB;MU[uPFYzPSEQvF2= NEXJVpFUSU6JRWK=
LoVo NX;oSllyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jZRWlEPTB;MU[uPVQ5QCEQvF2= M4G1NHNCVkeHUh?=
NCI-H2405 NYew[oFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEO5NYJKSzVyPUG3MlE6ODhizszN NVrDWG5vW0GQR1XS
AU565 M2Tlbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\a[2lEPTB;MUeuNlI2KM7:TR?= MmLrV2FPT0WU
OCI-AML2 MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInsbZNKSzVyPUG3MlU{OTdizszN MVrTRW5ITVJ?
22RV1 Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrBTohKSzVyPUG3MlU5QDRizszN NIXYfWtUSU6JRWK=
HT-144 Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfsVYZVUUN3ME2xO{43PTl6IN88US=> NF61cXBUSU6JRWK=
HuO9 M4K0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;EXJJKSzVyPUG3MlcxOzFizszN Mn7JV2FPT0WU
Daoy MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\FTYFLUUN3ME2xO{44OTh2IN88US=> Mln2V2FPT0WU
SJRH30 M1\OSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXZeHNKSzVyPUG3Mlg1QDlizszN MnXRV2FPT0WU
CHL-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLLTWM2OD1zNz65NlQ6KM7:TR?= M2exe3NCVkeHUh?=
J82 MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLoVmZKSzVyPUG3Mlk3OzVizszN M{T5OXNCVkeHUh?=
COR-L23 NF;ISI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfJTWM2OD1zOD6wNFEyKM7:TR?= NE\TcYJUSU6JRWK=
SNU-C2B MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Dlb2lEPTB;MUiuNlI4PiEQvF2= NWTFWIlyW0GQR1XS
NCI-H1770 MojIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHKVFVKSzVyPUG4MlQ3OTVizszN NW\hPVdKW0GQR1XS
MHH-PREB-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXpe2cxUUN3ME2xPE42Pjl5IN88US=> M{T5UXNCVkeHUh?=
ES3 NYHFNJV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPvOnlKSzVyPUG4MlU5QDNizszN M{fPR3NCVkeHUh?=
MDA-MB-231 M3iyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTF6Lk[1NFIh|ryP MlvPV2FPT0WU
MN-60 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXDS49KSzVyPUG5MlA2QTJizszN MXjTRW5ITVJ?
EPLC-272H NYHndYpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF7LkO3NFgh|ryP NXrtXYJzW0GQR1XS
SW948 M1LhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\ZRodDUUN3ME2xPU4{QTN2IN88US=> NGG0[m5USU6JRWK=
MOLT-13 NWPVXHhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrBcZNsUUN3ME2xPU41PTR4IN88US=> NVfybZdQW0GQR1XS
HL-60 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJyLkKxOFEh|ryP NI\CNpNUSU6JRWK=
CP50-MEL-B MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvobVhKSzVyPUKwMlQ4PDhizszN MY\TRW5ITVJ?
NTERA-S-cl-D1 M1;zdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jabGlEPTB;MkCuOFk4QCEQvF2= MoLiV2FPT0WU
KINGS-1 NYi5T3RyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jOSGlEPTB;MkCuO|k3PyEQvF2= MmXRV2FPT0WU
DOHH-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T0SmlEPTB;MkCuPVA3KM7:TR?= MYLTRW5ITVJ?
BB65-RCC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml36TWM2OD1{MD65Nlg2KM7:TR?= MlixV2FPT0WU
NB12 NYPRTmxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJzLkCzPVQh|ryP MV\TRW5ITVJ?
KY821 NFjRSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnRTWM2OD1{MT61PFIh|ryP NULmN|hzW0GQR1XS
PSN1 M4rSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLlcZZKSzVyPUKxMlY1PTNizszN MVXTRW5ITVJ?
EGI-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf0fHJKSzVyPUKxMlc1PTRizszN NYTuSpY3W0GQR1XS
CTV-1 NGTXcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnCNJZKSzVyPUKyMlMxOzFizszN M1XsU3NCVkeHUh?=
TI-73 MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzs[ZJKSzVyPUKyMlM1QThizszN M1PvT3NCVkeHUh?=
LCLC-103H MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJ{LkS3OVIh|ryP NXW5VFlJW0GQR1XS
D-542MG M2G2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVmzVZlCUUN3ME2yNk42PTV6IN88US=> MnXYV2FPT0WU
ATN-1 NU[4OGd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorGTWM2OD1{Mj62OFM6KM7:TR?= NVX1VYlyW0GQR1XS
SK-MEL-1 MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[4TWM2OD1{Mj64N|Y5KM7:TR?= MVHTRW5ITVJ?
HDLM-2 NYP0V3NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLYfHpKSzVyPUKzMlE1PzhizszN MlnFV2FPT0WU
UM-UC-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;zNpZKSzVyPUKzMlE6PDRizszN MUTTRW5ITVJ?
NCI-H1573 Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvme5h4UUN3ME2yN{41PjhzIN88US=> NVLEWmNUW0GQR1XS
NCI-H520 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfncGtiUUN3ME2yN{41QTR6IN88US=> M3HrdnNCVkeHUh?=
ESS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\iRlhZUUN3ME2yN{45ODV7IN88US=> NFfubY1USU6JRWK=
COR-L88 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvmfo5FUUN3ME2yN{46PDd3IN88US=> NVuzbGNSW0GQR1XS
TGBC24TKB MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrSZlJKSzVyPUK0MlA{OTJizszN NETEbJNUSU6JRWK=
HCC1937 NUjxd4JVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzYTWM2OD1{ND6xJO69VQ>? MlXxV2FPT0WU
RS4-11 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLpTWM2OD1{ND6xOFIh|ryP MXfTRW5ITVJ?
HCC38 MlPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\MTXc3UUN3ME2yOE4zOzl2IN88US=> MmLuV2FPT0WU
RPMI-2650 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDsTWM2OD1{ND62NVYzKM7:TR?= MkDLV2FPT0WU
P12-ICHIKAWA NETqWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzoT5dKSzVyPUK0MlYzPThizszN M{fSSXNCVkeHUh?=
YAPC Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG4[4h6UUN3ME2yOE45OjF2IN88US=> M3;QV3NCVkeHUh?=
NB13 NF[2S2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInseHJKSzVyPUK1MlI3OTFizszN NEDYOVFUSU6JRWK=
SK-N-AS MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jlOWlEPTB;MkWuPFU5PCEQvF2= NVL6eYhkW0GQR1XS
SK-N-DZ MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PNTmlEPTB;Mk[uNFQ6KM7:TR?= MXvTRW5ITVJ?
LS-411N M2GwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHGTWM2OD1{Nj6yNFM5KM7:TR?= MWXTRW5ITVJ?
NCI-H810 NYTab|hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ewOGlEPTB;Mk[uN|EyOiEQvF2= MkG0V2FPT0WU
NCI-SNU-1 NYnuNY94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPETWM2OD1{Nj61OFU1KM7:TR?= M3ru[nNCVkeHUh?=
HH Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJ4LkW1Nlkh|ryP M3PvWXNCVkeHUh?=
U-2-OS MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK1SZlKSzVyPUK2Mlc{QDJizszN NXTpflA{W0GQR1XS
SF539 MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjuXZdDUUN3ME2yOk45ODF6IN88US=> M3ftfXNCVkeHUh?=
NCI-H2052 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXmO2tKSzVyPUK3MlA5PiEQvF2= NYPPdYVrW0GQR1XS
A673 NGXpUmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJ5LkKxNFIh|ryP NGDXNVJUSU6JRWK=
WM-115 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYSzZYx[UUN3ME2yO{44PzZ5IN88US=> M3X4[HNCVkeHUh?=
SW48 M2PnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXiNIw1UUN3ME2yO{45ODB3IN88US=> M1TzcXNCVkeHUh?=
NOMO-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrGN5VKSzVyPUK3Mlg2OzJizszN NWPQN2ljW0GQR1XS
PC-3 NXv5T49WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJ5Lki5OFEh|ryP Mmr4V2FPT0WU
UMC-11 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETwe21KSzVyPUK3Mlk{PDNizszN NF;TeGhUSU6JRWK=
U-118-MG NFTwWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmi3TWM2OD1{OD6wNVI{KM7:TR?= NYnkVIxJW0GQR1XS
NCI-H2452 M{flZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\mb21KSzVyPUK4MlA5OjJizszN NHTjVXlUSU6JRWK=
CAMA-1 NFXUUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPm[HZPUUN3ME2yPE45PTZ2IN88US=> MoK3V2FPT0WU
MC-IXC NEHXUINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHDU4t5UUN3ME2yPU4zOzZ4IN88US=> MUHTRW5ITVJ?
ES4 M{WzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPvTWM2OD1{OT6zNVczKM7:TR?= NEfKNZVUSU6JRWK=
BHT-101 NYTqXplDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfrTWM2OD1{OT6zNlEh|ryP NXPtcZN2W0GQR1XS
KP-4 M1PH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTJ7LkWxOkDPxE1? M1\iOXNCVkeHUh?=
CAL-54 NWqwRm5WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Lk[mlEPTB;MkmuOVQ1PSEQvF2= NHrDOm5USU6JRWK=
5637 MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJ7Lk[0NlEh|ryP NFTNVFlUSU6JRWK=
MOLT-16 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DUT2lEPTB;MkmuO|I3QSEQvF2= NIj0Uo1USU6JRWK=
Ca-Ski MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fHfGlEPTB;MkmuPVQ3KM7:TR?= NVnjU4g6W0GQR1XS
AsPC-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Lx[2lEPTB;M{CuNFIyOiEQvF2= M3LVVXNCVkeHUh?=
MSTO-211H NHX1NIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUi1fZdLUUN3ME2zNE4yPSEQvF2= NHLWSZpUSU6JRWK=
L-428 MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTTR5FKSzVyPUOwMlQxPSEQvF2= M1HHc3NCVkeHUh?=
SW1463 NYj6clM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHToS|BKSzVyPUOwMlU{QDNizszN MVfTRW5ITVJ?
NCI-H1648 M1SxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITnZ4hKSzVyPUOwMlU2PzRizszN NVnOe4ZHW0GQR1XS
CAKI-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTzSXMyUUN3ME2zNE44PzB{IN88US=> Mk\tV2FPT0WU
YKG-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTNzLkCyOlMh|ryP NYPsOm9UW0GQR1XS
A2058 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\jRWlEPTB;M{GuNVE3PCEQvF2= NH;pbXlUSU6JRWK=
A375 MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1y3NmlEPTB;M{GuNVY6PiEQvF2= M12yTnNCVkeHUh?=
SNB75 NEXi[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWS4eW9TUUN3ME2zNU4zPDN3IN88US=> NETr[mFUSU6JRWK=
SK-HEP-1 MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTNzLkSyO|Eh|ryP NIS4RmhUSU6JRWK=
ME-180 NXvJd41ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTNzLk[1OFIh|ryP M{jnU3NCVkeHUh?=
NCI-H209 M2nL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;afmlEPTB;M{GuPFI1PyEQvF2= MXXTRW5ITVJ?
HC-1 MlSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTN{LkG0OFYh|ryP M3nUV3NCVkeHUh?=
LB373-MEL-D MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfLTWM2OD1|Mj6xPVcyKM7:TR?= NGDjfZlUSU6JRWK=
SNU-387 Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjP[pZJUUN3ME2zNk4{OTlzIN88US=> M1mzbnNCVkeHUh?=
C32 NXzZ[2l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHtWYVKSzVyPUOyMlM{PTNizszN MUDTRW5ITVJ?
EW-13 M37pd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XlO2lEPTB;M{KuPVQxQCEQvF2= M4jI[XNCVkeHUh?=
BFTC-905 M3L5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrLXmFKSzVyPUOzMlUyOzZizszN M2DJbnNCVkeHUh?=
NCI-H1299 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL1UG5KSzVyPUOzMlU3OjFizszN M4rmTHNCVkeHUh?=
LU-135 NIfaRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonoTWM2OD1|Mz64NFEh|ryP NWGzTWxjW0GQR1XS
NCI-H2122 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfDSWFCUUN3ME2zN{46QTZ4IN88US=> M{TWfXNCVkeHUh?=
SK-LMS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTN2LkSxNFch|ryP MoK4V2FPT0WU
LNCaP-Clone-FGC M1XrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTN2Lki1NVUh|ryP NFHNcoZUSU6JRWK=
NCI-H1092 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13nO2lEPTB;M{WuNlc1PyEQvF2= NGLPZohUSU6JRWK=
MS-1 MmnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHFTWM2OD1|NT6zNFM5KM7:TR?= MXTTRW5ITVJ?
KYSE-510 M33jTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XNTmlEPTB;M{WuOVA1OiEQvF2= MUDTRW5ITVJ?
NCI-H1793 NFrXcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTN3Lk[1OFUh|ryP M1jUTnNCVkeHUh?=
MIA-PaCa-2 NYLyeZpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTDTWM2OD1|Nj6wOFk3KM7:TR?= M1LEfHNCVkeHUh?=
EW-22 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTN4LkSwO|Ih|ryP NEPXbXFUSU6JRWK=
IGR-1 M3\Pd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nVV2lEPTB;M{[uPFE5PCEQvF2= Mn7nV2FPT0WU
HT-1080 MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7oc3lKSzVyPUO3MlEzPSEQvF2= M13tdXNCVkeHUh?=
M14 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTN5LkG2OFIh|ryP NVjVUmE5W0GQR1XS
786-0 M2\BPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTN5LkK3PVQh|ryP NYHQPXJJW0GQR1XS
MZ2-MEL MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTNTWM2OD1|Nz60OVAyKM7:TR?= MoXrV2FPT0WU
NCI-H510A MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnWZ4xKSzVyPUO3Mlk1OTJizszN NFvrNGxUSU6JRWK=
LAN-6 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTN5Lkm1PFIh|ryP MUXTRW5ITVJ?
SW620 M33CO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HEd2lEPTB;M{iuOFk4PCEQvF2= M{OyW3NCVkeHUh?=
LB2241-RCC MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLiTWM2OD1|OT64NlA2KM7:TR?= M4jZSHNCVkeHUh?=
Detroit562 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS2N2hYUUN3ME20NE4yOjZ6IN88US=> MXvTRW5ITVJ?
HN MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HRdWlEPTB;NECuNVc5OiEQvF2= NXTK[GY{W0GQR1XS
HCT-15 NYjsNXJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTRyLkW5NFch|ryP NYnqTlk1W0GQR1XS
C2BBe1 NFv3WnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\BTWM2OD12MD65NVU4KM7:TR?= NFz1dINUSU6JRWK=
A498 M17tW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTRzLkOwNVUh|ryP M3ixWnNCVkeHUh?=
SK-MEL-24 M3HmcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETsTmxKSzVyPUSxMlQ4OjVizszN NUPvO4JWW0GQR1XS
OVCAR-5 NGTrW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTRzLke3Olch|ryP MXfTRW5ITVJ?
NCI-H1792 NYSwOXg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHSTG5KSzVyPUSxMlk5OjFizszN M{D3ZXNCVkeHUh?=
KOSC-2 M2DvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTR{LkK2PVkh|ryP NETIfG1USU6JRWK=
Mo-T MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITBT3FKSzVyPUSyMlg6PThizszN NGP0T|ZUSU6JRWK=
CFPAC-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVu1cYdZUUN3ME20N{41QTR2IN88US=> M{npS3NCVkeHUh?=
CAL-51 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\nTWM2OD12Mz61OlA2KM7:TR?= NVv1SotkW0GQR1XS
RH-18 NF;kWXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTR|LkiwOUDPxE1? MY\TRW5ITVJ?
EC-GI-10 M4PqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorMTWM2OD12Mz64N|Q4KM7:TR?= NUS0UoJNW0GQR1XS
HSC-2 M2rxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr4cld4UUN3ME20OE4xODlizszN NFfITmFUSU6JRWK=
ML-2 M4C5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH0d|hKSzVyPUS1MlI3OjFizszN NXvWVYI4W0GQR1XS
KNS-81-FD Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXPSXRKSzVyPUS1Mlc{PjVizszN M2ezeXNCVkeHUh?=
NB6 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv4fWVKSzVyPUS2MlEyOSEQvF2= M2jXXXNCVkeHUh?=
MCF7 M1raZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTR4LkW1N|Mh|ryP NHPiPZdUSU6JRWK=
P30-OHK MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTR4LkixNVch|ryP MV3TRW5ITVJ?
BPH-1 NGrEZ2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL2V2x{UUN3ME20Ok46QDB3IN88US=> NXG3VIZOW0GQR1XS
U251 Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTUTWM2OD12Nj65PVQh|ryP M3zm[XNCVkeHUh?=
MKN1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofYTWM2OD12Nz61NVM4KM7:TR?= MVPTRW5ITVJ?
A431 NWr4bGNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[yTWM2OD12Nz64N|M5KM7:TR?= NFfH[2xUSU6JRWK=
C8166 MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknTTWM2OD12OT6yNFM6KM7:TR?= MnjHV2FPT0WU
HEL NIj4V|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj1NpU3UUN3ME20PU41ODZ2IN88US=> NVrBbGhpW0GQR1XS
RMG-I M{HpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXIOWl1UUN3ME20PU41PDR2IN88US=> M2ntU3NCVkeHUh?=
CAL-72 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUC0bG1wUUN3ME20PU43ODd3IN88US=> M1XiSnNCVkeHUh?=
SW962 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoS3TWM2OD12OT65N|MzKM7:TR?= NWfSU4JFW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-c-kit / c-kit / p-AKT / AKT / p-ERK / ERK / p-STAT3 / STAT3 / p-STAT5 / STAT5 / p-S6K / S6K / p-S6 / S6; 

PubMed: 31205508     


Immunoblotting analysis of indicated proteins in c-KIT mediated signaling pathways of GIST-T1, GIST-882, GIST-48B, and GIST-5R cell lines.

PARP / cleaved PARP / caspase-3 / cleaved caspase-3; 

PubMed: 31205508     


Immunoblotting analysis of apoptosis-related proteins after axitinib treatment in human GIST cell lines. Imatinib and sunitinib were used as positive controls.

31205508
Immunofluorescence
alpha-tubulin; 

PubMed: 26474283     


Representative images of RCC cells treated as above described, and then immunostained with anti-α-tubulin antibody. Bar: 50 μM

26474283
Growth inhibition assay
Cell viability ; 

PubMed: 26474283     


A. A-498 and Caki-2 RCC cell lines were cultured up to 96 h with different doses of axitinib. Cell viability was determined by MTT assay. Data shown are expressed as mean ± SD of three separate experiments; *p < 0.01 vs vehicle-treated cells. B. RCC cell 䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕€

26474283
In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

- Collapse

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

- Collapse
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
in solvent
Synonyms AG 013736
Smiles CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04522323 Recruiting Biological: MEDI5752|Drug: Axitinib Advanced Renal Cell Carcinoma MedImmune LLC August 5 2020 Phase 1
NCT04459663 Not yet recruiting Drug: Toripalimab injection combine with Axitinib Non-small Cell Lung Cancer Li Zhang MD|Sun Yat-sen University August 31 2020 Phase 2
NCT04337970 Recruiting Drug: Talazoparib|Drug: Axitinib Kidney Cancer|Renal Cell Carcinoma|Unresectable Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma Memorial Sloan Kettering Cancer Center April 6 2020 Phase 1|Phase 2
NCT04033991 Active not recruiting Drug: Sunitinib|Drug: Axitinib Carcinoma|Renal Cell Pfizer September 27 2019 --
NCT03472560 Active not recruiting Drug: Avelumab (MSB0010718C)|Drug: Axitinib (AG-013736) Non-Small Cell Lung Cancer|Urothelial Cancer Pfizer May 2 2018 Phase 2
NCT03538717 Completed -- Carcinoma Renal Cell Pfizer April 19 2018 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?

  • Answer:

    Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID